A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older
Latest Information Update: 16 Aug 2024
At a glance
- Drugs VXB 241 (Primary)
- Indications Metapneumovirus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
Most Recent Events
- 14 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2023 New trial record